AntiGrippin for children

General characteristics. Structure:

Active agents: paracetamol - 250 mg ascorbic acid - 50 mg of chlorphenaminum a maleate - 3 mg.            

Excipients: Natrii hydrocarbonas, citric acid, sorbitol, povidone, sodium saccharinate, sodium carbonate, macrogoal, silicon dioxide, fragrance fruit (aromatic fruit additive "Red Fruit").

Pharmacological properties:

The combined drug.

Paracetamol possesses analgetic and febrifugal action; eliminates head and other types of pain, reduces the increased temperature.

Ascorbic acid (vitamin C) participates in regulation of oxidation-reduction processes, carbohydrate metabolism, increases body resistance.

Chlorphenaminum - a blocker of H1-histamine receptors, possesses antiallergic action, facilitates breath through a nose, reduces feeling of a congestion of a nose, sneezing, dacryagogue, an itch and reddening of eyes.

Indications to use:

Infectious and inflammatory diseases (SARS, flu) which are followed by the increased temperature, a fever, a headache, joint pains and muscles, a congestion of a nose and pharyngalgias and nose bosoms.

Route of administration and doses:

Inside. To children from 3 to 5 years on 1/2 tablets 2 times a day; children are from 5 to 10 years old on 1 tablet 2 times a day; children are from 10 to 15 years old on 1 tablet 2-3 times a day. The tablet should be dissolved completely in a glass (200 ml) of warm water (50-60 °C) and at once to drink the received solution. It is better to accept drug between meals. The interval between administrations of drug has to be not less than 4 hours.
At patients with abnormal liver functions or kidneys the interval between administrations of drug has to make not less than 8 hours.

Reception duration without consultation with the doctor no more than 5 days at appointment as anesthetic and 3 days as an antipyretic.

Features of use:

At reception of Metoclopramidum, domperidon or Colestyraminum it is also necessary to consult with the doctor.
At prolonged use in the doses considerably exceeding recommended the probability of an abnormal liver function and kidneys increases, control of a peripheral picture of blood is necessary.
Paracetamol and ascorbic acid can distort indicators of laboratory researches (quantitative determination of content of glucose and uric acid in a blood plasma, bilirubin, activity of "hepatic" transaminases, LDG).
Purpose of ascorbic acid to patients with quickly proliferating and intensively metastasizing tumors can aggravate the course of process. At patients with the increased content of iron in an organism it is necessary to apply ascorbic acid in the minimum doses.

Side effects:

Drug is well transferred in the recommended doses.

In isolated cases meet:
- from TsNS: headache, feeling of fatigue;
- from a GIT: nausea, pain in epigastric area;
- from endocrine system: a hypoglycemia (up to development of a coma);
- from bodies of a hemopoiesis: anemia, hemolitic anemia (especially for patients with deficit glyukozo-6-fosfatdegidrogenazy); extremely seldom – thrombocytopenia;
- allergic reactions: skin rash, itch, small tortoiseshell, Quincke's edema;
- others: a hypervitaminosis, disbolism, feeling of heat, dryness in a mouth, accommodation paresis, an ischuria, drowsiness.
It is necessary to report about all side effects of drug to the doctor.

Interaction with other medicines:

Ethanol strengthens sedative effect of antihistaminic drugs.
Antidepressants, protivoparkinsonichesky means, antipsychotic means (derivatives of a fenotiazin) - increase risk of development of side effects (an ischuria, dryness in a mouth, locks). Glucocorticosteroids - increase risk of development of glaucoma.

At simultaneous use reduces chronotropic action of an izoprenalin.

Reduces therapeutic effect of antipsychotic drugs (neuroleptics) - derivatives of a fenotiazin, a canalicular reasorbtion of amphetamine and tricyclic antidepressants.

Inductors of a microsomal oxidation in a liver (Phenytoinum, ethanol, barbiturates, rifampicin, phenylbutazone, tricyclic antidepressants) increase products of hydroxylated active metabolites that causes a possibility of development of heavy intoxications at small overdoses. Ethanol promotes development of acute pancreatitis.

Inhibitors of a microsomal oxidation (including Cimetidinum) reduce risk of a hepatotoxic action. The concomitant use of drug and a diflunisal increases concentration in a paracetamol blood plasma for 50%, a hepatotoxic raises. The concomitant use of barbiturates reduces efficiency of paracetamol, increases removal of ascorbic acid with urine.

Paracetamol reduces efficiency of uricosuric drugs.

Contraindications:

Hypersensitivity to paracetamol, ascorbic acid, chlorphenaminum or any other component of drug; digestive tract erosive cankers (in an aggravation phase); the expressed renal and/or liver failure; closed-angle glaucoma; children's age (up to 3 years).

With care – a renal and/or liver failure, deficit glyukozo-6-fosfatdegidrogenazy, inborn hyperbilirubinemias (Gilbert's syndromes, the Cudgel Johnson and the Rotor), a viral hepatitis.

Overdose:

Overdose symptoms drug are caused by the substances which are its part. The clinical picture of acute overdose by paracetamol develops within 6-14 hours after its reception. Symptoms of chronic overdose are shown in 2-4 days after increase in a dose of drug. Symptoms of acute overdose of paracetamol: diarrhea, a loss of appetite, nausea and vomiting, discomfort in an abdominal cavity and/or abdominal pain, increase in sweating.
Symptoms of overdose of chlorphenaminum: dizziness, excitement, sleep disorders, depression, spasms.

Treatment: symptomatic.

Storage conditions:

At a temperature of 10-30 °C. To store in the place, unavailable to children!

Issue conditions:

Without recipe

Packaging:

Tablets sparkling for children.
On 10 tablets in a plastic case or in the blister from PVC/Al; on 2, 4 or 6 tablets in a strip from Al/Al.
On 1, 2, 3, 4, 5 blisters or on 5, 10, 15, 20 strips in a cardboard pack together with the application instruction.
On 1 case in a cardboard pack or in a pack envelope with the device for suspension together with the application instruction.